Related Experiment Video
Updated: Mar 18, 2026

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth.
1Scientific Research Center for Translational Medicine, Department of Biotechnology, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.
A novel Rheb mutation (Rheb-Y35N) drives cancer by activating mTORC1 and MAPK pathways, conferring resistance to rapamycin. This Rheb mutation promotes aggressive tumor growth, suggesting combined mTORC1 and MAPK inhibition as a therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Rheb (Ras homolog enriched in brain) is a GTPase activating the mTORC1 pathway.
- Recurrent Rheb Tyr35Asn mutations are found in kidney and endometrial cancers.
Purpose of the Study:
- Investigate the functional consequences of Rheb Tyr35Asn mutations.
- Determine the role of Rheb-Y35N in cancer development and therapeutic resistance.
Main Methods:
- Cellular assays to assess mTORC1 and MAPK pathway activation.
- Xenograft mouse models to evaluate tumor formation and treatment response.
- Biochemical assays to analyze Rheb-AMPK interactions.
Main Results:
- Rheb-Y35N causes constitutive mTORC1 and sustained, mTORC1-independent MEK-ERK pathway activation.
- Rheb-Y35N promotes aggressive tumor growth in vivo and confers resistance to rapamycin.
- Rheb-Y35N inhibits AMPK activation by competitively binding AMPK, impairing its phosphorylation.
Conclusions:
- Rheb-Y35N is a potent oncogenic driver activating both mTORC1 and MAPK pathways.
- Combined mTORC1 and MAPK inhibition may be a valuable therapeutic approach for cancers with Rheb-Y35N mutations.
More Related Videos
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation